Obviously, SIJ1777 is clearly superior to vemurafenib and PLX8394 not only in terms of cellular potency but also inhibitory effects on MAPK/AKT signaling, migration/invasion, and colony formation on melanoma cells harboring BRAF class II/III mutations. This evidence concerns the gene BRAF and melanoma.